Pulmatrix Announces Presentation of Clinical Data Demonstrating iCALM Inhaled Therapeutic Reduced Airway Inflammation
5/22/2012 10:58:17 AM
LEXINGTON, Mass.--(BUSINESS WIRE)-- Pulmatrix, a biotechnology company developing breakthrough therapies for respiratory diseases, today announced the results of a clinical study showing that an iCALM™ (inhaled cationic airway lining modulator therapy) attenuated allergen-induced bronchitis in susceptible asthmatic patients. This demonstration of iCALM’s anti-inflammatory effect, as manifest by the reduction of eosinophils in the airways after allergen challenge, supports the conclusion that iCALM is a novel inhaled therapeutic with a previously unexplored mechanism of action that can lead to better control of symptoms and lung function in patients with chronic airway diseases. These clinical data were presented at the American Thoracic Society (ATS) 2012 International Conference on Monday, May 21, 2012, in San Francisco, CA.